225 related articles for article (PubMed ID: 36193597)
1. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer.
Khan A; Sarkar E
Cancer Treat Res Commun; 2022; 33():100641. PubMed ID: 36193597
[TBL] [Abstract][Full Text] [Related]
2. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Sarkar E; Khan A
Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
[TBL] [Abstract][Full Text] [Related]
3. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
5. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
6. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.
Ureña-Bailén G; Lamsfus-Calle A; Daniel-Moreno A; Raju J; Schlegel P; Seitz C; Atar D; Antony JS; Handgretinger R; Mezger M
Brief Funct Genomics; 2020 May; 19(3):191-200. PubMed ID: 31844895
[TBL] [Abstract][Full Text] [Related]
8. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
Quazi S
Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
[TBL] [Abstract][Full Text] [Related]
11. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
[TBL] [Abstract][Full Text] [Related]
13. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
15. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
16. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
20. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
